ESMO pre-"research" news The development of domestic anti-PD-1 monoclonal antibodies is eye-catching, and the results of the phase II trial of paimpril combined with allotinib are outstanding

Abstract number: 1743P

：ALTN-AK105-II-02 cohort 4: A phase II study of penpulimab plus anlotinib in patients (pts) with previously treated locally advanced or metastatic urothelial carcinoma (UC)

Immune checkpoint inhibitors (ICIs) have been approved for the treatment of patients with advanced/metastatic UC who have failed platinum-based chemotherapy

Patients in Cohort 4 were enrolled in 18 years of age or older, with metastatic or unresectable locally advanced UC, had previously failed treatment with at least 1 systemic standard chemotherapy regimen, had measurable lesions defined by RECIST V1.

A total of 15 patients were enrolled from September 2020 to April 2022, with a median follow-up of 9.

After receiving treatment, the patients had ANR of 33.

Treatment-related adverse events (TRAEs) of any level were most commonly seen in hypertension (66.
7%), hand-foot syndrome (46.
7%), hypothyroidism, hyponatremia, and proteinuria (40.
0%
each).

Six (40%) patients developed grade 3 TRAEs, the most common of which was hypertension (20%), and 1 (6.
7%) discontinued paemprizumab
due to myocarditis (grade 3).

No 4-5 TRAEs have occurred
.

The results of this Phase II study showed that paemprizumab plus anlotinib showed good antitumor activity and safety in patients with advanced/metastatic UC who failed platinum chemotherapy
.

Reference source:Wang Mumu

Reviewed: LR

Executive: Wang Mumu